Who is sponsoring NCT00720278?

NCT00720278 is sponsored by Meda Pharmaceuticals.

What drugs are being tested in NCT00720278?

Interventions in NCT00720278: 0.15% azelastine hydrochloride 1644 mcg daily, 0.1% azelastine hydrochloride 1096 mcg daily, Placebo.

What condition does NCT00720278 study?

NCT00720278 studies Seasonal Allergic Rhinitis.

Is NCT00720278 still recruiting?

NCT00720278 is currently completed. Last updated 19 February 2010.

Are results published for NCT00720278?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2010-02-19 · How we verify

NCT00720278

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of MP03-36 and MP03-33 Compared to Placebo in Patients With Seasonal Allergic Rhinitis

Completed Phase 3 Results posted Last updated 19 February 2010

What this trial tests

Phase 3 trial testing 0.15% azelastine hydrochloride 1644 mcg daily in Seasonal Allergic Rhinitis in 526 participants. Completed in 1 November 2007.

Timeline

1 August 2007

Primary endpoint
1 October 2007

1 November 2007

Quick facts

Lead sponsor	Meda Pharmaceuticals
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	526
Start date	1 August 2007
Primary completion	1 October 2007
Estimated completion	1 November 2007
Sites	29 locations across United States

Drugs / interventions tested

0.15% azelastine hydrochloride 1644 mcg daily — full drug profile →
0.1% azelastine hydrochloride 1096 mcg daily — full drug profile →
Placebo

Conditions studied

Seasonal Allergic Rhinitis — all drugs for Seasonal Allergic Rhinitis →

Sponsor

Meda Pharmaceuticals — full company profile →

Who can join

12 and older, any sex, with Seasonal Allergic Rhinitis. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Change From Baseline in 12-hour Reflective Total Nasal Symptom Score(rTNSS)for the Entire 14-day Study Period Compared to Placebo
Time frame: baseline and 14 days
rTNSS consisting of runny nose, itchy nose, nasal congestion, and sneezing was assessed twice daily. Each symptom is rated on a scale from 0-3: 0=none, 1=mild, 2=moderate, and 3=severe. (maximum 12 points per assessment.) Total possible score is 24 per day. Least square means was controlled for study day as the within-patient effect, treatment group and site as the between-patient effects, treatm

Sponsor's own description

The purpose of this study was to determine if two allergy medications are more effective than placebo.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Seasonal Allergic Rhinitis

Currently open trials in the same condition.

NCT07055542 — Creating A Risk Assessment Tool for Thunderstorm Asthma: the CARISTA Study · NA · recruiting
NCT06846385 — Phase II/III Seamless Clinical Study of MG-K10 Humanized Monoclonal Antibody Injection in Treatment of Seasonal Allergic · Phase 2, PHASE3 · recruiting
NCT07291284 — Efficacy and Safety of LP-003 Injection in Patients With Moderate to Severe Seasonal Allergic Rhinitis · Phase 3 · active not recruiting
NCT06300203 — Study of CM310 in Patients With Uncontrolled Seasonal Allergic Rhinitis · Phase 2 · recruiting
NCT04815668 — Acupuncture at the Sphenopalatine Ganglion in the Treatment of Moderate-to-severe Seasonal Allergic Rhinitis · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00720278 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Meda Pharmaceuticals
Last refreshed: 19 February 2010

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00720278.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing